A look back at RESCON Summit USA 2025 — bringing together experts in inhalation and respiratory drug delivery, connected devices and emerging therapeutic technologies.
This page is an archive of the 2025 event. For upcoming RESCON participation, use the current registration and sponsorship pages.
RESCON Summit 2025 brought global leaders from pharmaceutical, biotechnology and device companies to San Francisco on 5–6 November to discuss advances in inhalation and respiratory drug delivery.
The programme explored the development pathway from inhaled formulations and nanocarriers to dry-powder devices, soft mist technologies, connected health, regulatory strategy and commercial collaboration.
Beyond the presentations, the event created space for technical discussion, networking and partnerships across the respiratory value chain.
Explore the ten scientific and technical themes from the original 2025 event overview.
Gain exposure to the latest in non-invasive drug delivery systems, including soft mist inhalers, nasal powders, and epithelial delivery routes, aiming to eliminate syringes and expand therapeutic access.
Explore formulation strategies for inhalable nanocarriers, microparticles, and combination products, optimizing lung targeting, therapeutic efficacy, and stability.
Understand how engineering design, realistic testing models, and patient-centric considerations impact the real-world performance and acceptance of DPIs.
Discover integrated approaches combining human ex vivo and in vivo data to enhance the safety, efficacy, and predictivity of respiratory drug development.
See how digital inhalers, remote monitoring, and connected health platforms are shaping the future of adherence tracking, clinical insights, and patient engagement.
Navigate FDA and EMA pathways for complex inhaled combination products, including considerations for nebulized gene therapies and evolving environmental standards.
Learn how the transition to low global warming potential (GWP) propellants and eco-conscious design is reshaping the respiratory device landscape.
Analyze how open and closed claims data, cost-of-illness studies, and economic modeling inform access strategies for rare and chronic respiratory conditions.
Examine how usability studies, connected technologies, and human factors research drive more intuitive and effective inhalation therapies tailored to patient needs.
Understand scientific advancements in airway mucosal remodeling, aerosol therapy, and the potential of inhaled biologics and ions for systemic and localized effects
Scientific exchange was complemented by networking, panel discussions and time with the wider respiratory community.
Watch the event highlights, then browse the photo report for a closer look at the people and conversations behind RESCON Summit 2025.
Watch the 2025 video ↗View the photo report ↗Senior decision-makers and technical specialists across pharmaceutical, respiratory device and supporting technology sectors.
Device development and engineering; inhalation devices; new delivery technologies; medical devices.
Respiratory R&D; drug development; inhaled formulation science; respiratory pharmacology.
Respiratory regulations; particle characterisation; process development; packaging.
Board members; CEOs; VPs; directors; business development; outsourcing; commercial functions.
A selection of the contributors from the San Francisco programme, spanning pharma, device development, manufacturing and respiratory science.
Selected names shown. Explore the original speakers page for the complete roster.
View all 2025 speakers ↗All the original RESCON 2025 resources in one place: agenda, speakers, venue, partners and media.
Our past editions are part of an ongoing conversation across inhalation and respiratory drug delivery. Explore the opportunities to join the next summit as a delegate or partner.